… synthetic disease- modifying antirheumatic drugs (DMARDs) and/or … planned to continue
their antirheumatic medications, a … of COVID- 19 among patients taking antirheumatic drugs are …

… The primary outcome was the occurrence of a positive COVID-19 test result during the study
… various antirheumatic drugs intake, COVID-19 risk factors, and occurrence of COVID-19 …

… The aim of this narrative review is to analyze the mechanistic rationale and available evidence
for selected anti-rheumatic drugs for the treatment of COVID-19. The data for this review …

… To determine whether the use of disease-modifying antirheumatic drugs (DMARDs) is
linked to the risk of COVID-19 among patients with inflammatory rheumatic diseases (IRDs). …

… understanding of the COVID-19 has led to a growing interest in certain drugs used in these
… The rational for use of other antirheumatic drugs is based on the inflammatory reaction …

… the COVID-19 pandemic is progressing rapidly in all countries.2 As of 10 April 2020, COVID-19
… receive glucocorticoids and disease-modifying anti-rheumatic drugs (DMARDs) (table 1), …

… Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination
with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95…

… COVID-19 pandemic in the management of their patients and many questions have been
raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (…

… Anti rheumatic drugs are often associated with viral and bacteriological infectious … drugs
used in commonly used Rheumatology could also be used for Covid-19 Rheumatological drugs …

… the risks of increased incidence of COVID-19 in vulnerable patient groups, … antirheumatic
drugs, including biologics. So far, results on the incidence and the outcomes of COVID-19 in …